Gilead Sciences (GILD) DIvidends Date & History

Key Takeaways

• Gilead Sciences offers a current dividend yield of 2.38%, providing a steady income stream in the volatile biotech sector.
• Quarterly dividend of $0.82 per share, with forward annual payout of $3.28.
• 10 consecutive years of dividend increases, averaging about 3% annual growth over the past five years.
• Payout ratio of approximately 47%, indicating strong sustainability backed by robust free cash flow.
• Recent ex-dividend date was March 13, 2026, with payment on March 30, 2026.
• Competitive yield among dividend-paying biotech peers like AMGN (around 2.8%).

Dividend Overview

Gilead Sciences (GILD), a leading biopharmaceutical company focused on HIV, oncology, and inflammatory diseases, maintains a reliable quarterly dividend policy. The current forward annual dividend is $3.28 per share, yielding 2.38% based on a recent stock price of approximately $137.64. Payments occur every three months, with the most recent ex-dividend date on March 13, 2026, and payment on March 30, 2026, at $0.82 per share. This positions GILD as a modest dividend growth stock rather than a high-yield play, appealing to investors seeking stability amid biotech sector fluctuations. The five-year average yield is 3.69%, reflecting a consistent profile.

Dividend History and Growth

Gilead Sciences initiated its dividend in 2015 with an annual payout of $1.72 per share and has since raised it steadily to $3.28 forward annually, achieving a compound annual growth rate (CAGR) of approximately 6% over the decade. The company announced a 3.8% increase for the first quarter of 2026, bringing the quarterly dividend to $0.82. This marks 10 consecutive years of dividend growth without any cuts, demonstrating commitment to shareholders. The long-term strategy emphasizes balancing reinvestment in R&D (research and development) with reliable distributions, supporting a profile of consistency in a growth-oriented industry.

Dividend Sustainability and Payout Ratio

The payout ratio for GILD is 46.61%, meaning less than half of earnings are distributed as dividends, leaving ample room for growth and reinvestment. Free cash flow coverage is strong, with a cash payout ratio around 30-40%, bolstered by $4.1 billion in operating cash flow in Q3 2025 alone. Moderate debt levels and consistent profitability further enhance sustainability. Projections suggest the ratio could dip to 39-40% next year amid expected EPS growth, affirming long-term viability.

Dividend Compared to Industry Peers

In the biotechnology sector, where many firms like VRTX and REGN pay no dividends, GILD's 2.38% yield stands out. Among paying peers, it is slightly below AMGN (2.7-3.1%) and ABBV (3.3%), but competitive with the industry's low average yield. Larger pharma like PFE offer higher yields, but GILD provides a balanced biotech option with growth potential.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.

Is This Stock Attractive for Dividend Investors?

Gilead Sciences (GILD) may appeal to conservative dividend growth investors seeking reliable quarterly income with moderate yield in the biotech space. Its 10-year streak of increases and sub-50% payout ratio suit those prioritizing sustainability over high yields, especially given strong cash flow coverage. Income-focused portfolios could benefit from the 2.38% yield amid sector volatility, while long-term holders might value the balance of R&D investment and shareholder returns. However, biotech risks like patent cliffs and regulatory hurdles warrant caution for yield-chasing investors preferring higher payers like utilities. Overall, it fits balanced, defensive strategies in healthcare.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations